Zerbaxa Approved for Hospital-Acquired Bacterial Pneumonia

0
92

Skip to Content Zerbaxa Approved for Hospital-Acquired Bacterial Pneumonia

TUESDAY, June 11, 2019 — Zerbaxa (ceftolozane and tazobactam) has been approved for a new indication to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older, the U.S. Food and Drug Administration announced yesterday.

In 2014, the FDA first approved Zerbaxa for treating complicated intra-abdominal infections and urinary tract infections. According to the manufacturer's prescribing information, Zerbaxa is administered in a recommended dosage regimen of a 1.5-g injection every eight hours by intravenous infusion for one hour. Treatment duration should be based on the infection site and severity and the patient's progress.

In a multinational, double-blind study of 726 patients hospitalized with HABP/VABP who were injected with Zerbaxa or another antibacterial drug, researchers found similar mortality and cure rates between the two drugs. The most commonly reported adverse reactions among patients treated with Zerbaxa included elevated liver enzyme levels, renal impairment or failure, and diarrhea.

The FDA notes that Zerbaxa should not be used in patients known to have serious hypersensitivity to the drug's components or to piperacillin/tazobactam or other antibacterial drugs in the beta lactam class.

Approval of Zerbaxa for this new indication was granted to Merck and Co.

More Information

© 2019 HealthDay. All rights reserved.

Posted: June 2019

More News Resources

Antibiotics 101

Latest Drug Information Updates

  • Slynd Slynd (drospirenone) is a progestin oral contraceptive for birth control.
  • Piqray Piqray (alpelisib) is a kinase inhibitor indicated in combination with fulvestrant for the treatment of…
  • Nayzilam Nayzilam (midazolam) is a nasally administered benzodiazepine indicated for the acute treatment of seizure…
  • Qternmet XR Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) is a sodium-glucose cotransporter 2…
  • Skyrizi Skyrizi (risankizumab-rzaa) is an interleukin-23 (IL-23) inhibitor for the treatment of plaque psoriasis.
  • Balversa Balversa (erdafitinib) is a once-daily, oral, pan-fibroblast growth factor receptor for the treatment of…
  • More updates

Subscribe to our newsletters Original Article

LEAVE A REPLY

Please enter your comment!
Please enter your name here